Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27.98 DKK | +0.45% | -3.30% | -18.50% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 10.94 for the current year and 9.57 for next year, earnings multiples are highly attractive compared with competitors.
- The company has a low valuation given the cash flows generated by its activity.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.50% | 4.52B | B- | ||
+14.12% | 69.43B | C+ | ||
+5.02% | 7.98B | B | ||
-2.98% | 7.79B | C | ||
-27.52% | 7.13B | B- | ||
+21.54% | 4.39B | B+ | ||
-2.45% | 3.98B | B- | ||
-4.19% | 3.82B | B | ||
+23.90% | 3.64B | C+ | ||
+4.57% | 3.28B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HLUN B Stock
- LUN Stock
- Ratings Lundbeck